Claims Scope:

Allowed.  Issue fee due March 11, 2024. 

Sequence agnostic claims – Comp & Methods 

Comp, method and immunotherapy claims to a vector encoding microRNA or shRNA that, when expressed, inhibits production of farnesyl diphosphate synthase and activates a gamma delta (GD) T cell. Dependent claims to 80%, 90% or 95% SID to SEQ ID NOs: 1-10. Combination claims also include amino bisphosphonates.